Patrys has PAT-SM6 trial studies published

THE ROADHOUSE PHARMACY: Patrys Limited (ASX: PAB) had had results from its recent PAT-SM6 Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma(MM) published in peer-reviewed journal. Haematologica.

Patrys claims the article provides a summary of the results of the clinical study conducted in twelve heavily pre-treated MM patients that received four escalating doses of PAT-SM6, over a period of two weeks, via intravenous infusions at 0.3, 1, 3, and 6 mg/kg doses.

The company said safety and tolerability, which were the primary objectives of the study, have been supported with all doses administered found to be safe, well tolerated and the maximum tolerated dose (MTD) not reached.

Four out of twelve patients (33.3 per cent) had stable disease after PAT-SM6 treatment across the dose cohorts 1, 3 and 6 mg/kg according to the International Myeloma Working Group (IMWG) criteria.

According to Patrys the data is comparable to other antibodies under clinical development for the treatment of MM.

“Treatment of relapsed-refractory MM continues to present a therapeutic challenge, prompting a continued search for additional therapeutic options,” Patrys said in its ASX announcement.

“The trial results are also important because they reflect in vivo activity in a difficult-to-treat patient population.

“Targeting GRP78, which is responsible for resistance in many cancers, highlights the prospective role of PAT-SM6 in combination with the existing therapies to overcome tumour resistance.

“Furthermore, the favorable safety profiles of PAT-SM6 make it a likely candidate for possible synergistic results in combination with other therapies while maintaining low toxicity.”

Patrys indicated the upcoming publication also includes supplementary data on an observation made during the course of the trial regarding immune mechanisms of PAT-SM6 and its possible role in overcoming tumour resistance.

Email: info@patrys.com

Website: www.patrys.com